TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: (M) further involves heat treating (I). LP is selected from L.tropica, L.mexicana, L.guyanensis, L.braziliensis, L.major, L.donovani, L.chagasi, L.amazonensis, L.peruviana, L.panamensis, L.pifanoi, L.infantum and L.aethiopica.Preferred Kit: The kit further comprises at least one pharmaceutical e.g. epinephrine, diphenhydramine or methyl prednisolone, for treating systemic anaphylaxis, or at least one pharmaceutical e.g. hydrocortisone, hydrocortisone cream, acetaminophen or diphenhydramine, for treating local reactions to (I).Preferred Composition: In PC, the pharmaceutically acceptable stabilizer is phenol. The composition is in the form of a liquid, may be frozen or freeze-dried. ACTIVITY - Protozoacide.    MECHANISM OF ACTION - Vaccine.    No supporting data is given.    ADMINISTRATION - 5-30 mug of (I) is administered intradermally to the volar surface of the fore-arm of the subject (claimed).    EXAMPLE - Source material and production of a research seed for the Leishmania guyanensis skin Test, LSTA-Lg (BPR- 2334-RS) was conducted as follows. A parasite specimen was obtained from an active dermal lesion from a human subject otherwise healthy with unremarkable medical history. The subject tested negative in screening with viral/sexually transmitted disease (STD) panel (human immunodeficiency virus (HIV), human T lymphotrophic virus (HTLV), cytomegalovirus (CMV), hepatitis C virus (HCV), hepatitis B virus (HBV) and syphilis). The subject's travel history was determined. The absence of adventitious agents in all media components used in manufacturing process was determined and the fetal bovine serum (FBS) Type II, was mycoplasma and bovine virus tested, screened for bacteriophage, tested for endotoxin, tested for AVA, cell culture tested and heat-inactivated. The promastigotes cultured form this specimen, (strain WR2334), were determined by isoenzymes to be L.guyanensis. No known viral contaminants, such as LRV1- 4, were detected in the promastigotes. A clonal line, WR2334 clone D2 (WR2334-D2), was established through serial endpoint dilution and microscopic visualization of a single promastigote. This source seed stock of this clone was then expanded in culture, aliquoted and cryopreserved in liquid nitrogen. Sterility and morphology were determined by conventional methods. A master cell bank for the L.guyanensis (WR2334-Clone D2) Leishmania Skin Test, LSTA-Lg (BPR-377-00, Lot No. 0705) was manufactured under defined cGMP conditions from cryopreserved aliquots of WR2334-Clone D2, by culturing and expansion to roller bottles in appropriate medium. The cultured promastigotes were harvested by centrifugation, washed, suspended in cryopreservation medium, aliquoted and stored in liquid nitrogen. Sterility and morphology were determined by conventional methods. A working cell bank was prepared from the above master cell bank by a similar technique, and a bulk lot was also produced. Specifically, bulk promastigotes were cultured in Schneider's Drosophila Medium (SDM), supplemented with 20% FBS (heat inactivated). The inoculum was initiated in flasks and when the culture set point was reached, it was transferred to roller bottles and expanded. Promastigotes were harvested by centrifugation when a sufficient quantity was obtained. The culture was maintained in healthy, log-growth phase throughout the production run, including the time of harvest. Harvested promastigotes were centrifuged, and the pellets were reconstituted in sterile saline USP and manually filled in 5.0 ml aliquots at 109 promastigotes/ml. The vials were labeled, stored and frozen at -80degreesC for subsequent production and purification. Sterility and morphology were determined by conventional methods. The bulk for L.guyanensis (WR2334- Clone D2) Leishmania Skin Test, LSTA-Lg (BPR-377-00, Lot No. 0716) was purified. Specifically, cryopreserved vials were thawed and processed through a microfluidizer. The material was centrifuged, and the pellet was resuspended and microfluidized again (MFL2). The material was centrifuged and the two supernatants combined. The pooled supernatants were placed in a 0.22 micron sterile filter unit (500 ml) and filtered. The filtrate was then heat-treated at 90degreesC for 15-20 minutes to inactivate parasite proteases. The final filtered and heat- treated bulk was formulated and the protein concentration adjusted to 0.35 mg/ml. The bulk material was tested for color, protein content, purity and identity, quality and sterility. The final product of L.guyanensis (WR2334-Clone D2) Leishmania Skin Test, LSTA-Lg (BPR-377-00, Lot No. 0717) was placed in vials. Specifically, the formulated, bulk LSTA-Lg was aseptically filled in 1.0 ml aliquots into 10 ml Type I glass vials, closed with 20 mm rubber closures and stored at 4degreesC. The samples were tested for the above said characteristics, as well as for rabbit pyrogenicity, general safety, endotoxin (LAL), pH, potency, in vivo immunogenicity and stability.